NASDAQ: NAGE
Niagen Bioscience Inc
Healthcare · Biotechnology
After hours: $3.05(-0.28%) · as of 7:34 PM ET
Market Cap
$243.71M
52w High
$10.52
52w Low
$2.87
P/E
15.79
Volume
386.52K
Outstanding Shares
79.64M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 70.18% over the last year. Revenue grew 10.99% over the trailing twelve months. Operating margin moved from 14.33% to 6.67%. Free cash flow declined 72.9% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/FCF, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at 6.67%. Free cash flow fell 72.9% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging.
Valuation
Stock splits
Every 3 shares became 1
Profitability & growth
Analyst consensus
5
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 3, 2026
Q4 FY26 · EPS est $0.01 · Revenue est $34.45M
View